GSK press releases Follow Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7. https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma/ gsk.com
